Medication Safety - Formulary

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

Medication Safety

Thiopurines increase lymphoproliferative disorder risk in IBD patients

November 1, 2009

Patients with inflammatory bowel disease receiving thiopurines are at increased risk of developing lymphoproliferative disorder, according to a French prospective observational cohort study, which was published online in The Lancet.

Two antimalaria drugs are tolerated regimens in regions with resistance

November 1, 2009

In a review published in The Cochrane Library, researchers determined that atovaquone-proguanil and doxycycline were well tolerated by most travelers and are less likely than mefloquine to cause adverse neuropsychiatric outcomes.

Bloodstream infections and contaminated prefilled syringes: issues of medication safety

November 1, 2009

An investigation into a multistate outbreak of Serratia marcescens bloodstream infections (BSIs) published in the Archives of Internal Medicine found an association between the BSIs and contamination of prefilled syringes.

Specialty pharmacy's role in REMS, FDA's new drug safety program

October 1, 2009

Specialty pharmacies are uniquely positioned to play a key role in the implementation of Risk Evaluation and Mitigation Strategies (REMS).

FDA issues early communication about ongoing safety review of orlistat

September 14, 2009

FDA is reviewing reports of liver injury in patients treated with orlistat (prescription drug, Xenical; OTC drug, Alli) for obesity management or weight loss.

Mycophenolic acid associated with increased risk of pure red cell aplasia

September 14, 2009

Novartis has issued a Dear Healthcare Professional letter regarding a risk of pure red cell aplasia (PRCA) in patients treated with mycophenolic acid (Myfortic).

Leukotriene inhibitors associated with neuropsychiatric events

September 14, 2009

In an update to an earlier communication, FDA announced that the manufacturers of the leukotriene inhibitors montelukast (Singular), zafirlukast (Accolate), zileuton (Zyflo), and zileuton extended-release (Zyflo CR) are adding information about neuropsychiatric events to product labeling.

Etravirine associated with severe skin and hypersensitivity reactions

September 14, 2009

Tibotec has issued a Dear Healthcare Professionals letter regarding an increased risk of fatality caused by toxic epidermal necrolysis and hypersensitivity reactions, sometimes accompanied by hepatic failure, in patients treated with etravirine (Intelence).

Trial of sildenafil for PAH in patients with sickle cell disease terminated because of safety concerns

August 18, 2009

The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) has prematurely terminated a trial of sildenafil for the treatment of pulmonary arterial hypertension (PAH) in adult patients with sickle cell disease because of safety concerns.

ADVERTISEMENT



Stay connected to Formulary
Receive web-exclusive articles, clinical news, and conference updates!

ADVERTISEMENT

Modern Medicine logoFormulary archives are now available on ModernMedicine.com, a new online resource designed to meet the evolving needs of physicians.
Register now (it's free and quick) or Find out more.

Keep visiting FormularyJournal.com for fresh content, news, opinions, editor's blogs and more.

ADVERTISEMENT

Click here